WS
AZN icon

Wedbush Securities’s AstraZeneca AZN Stock Holding History

Wedbush Securities’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Sell
6,964
-86
-1% -$16.6K 0.04% 360
2025
Q4 		$1.3M Buy
7,050
+1,454
+26% +$255K 0.04% 366
2025
Q3 		$859K Buy
5,596
+1,282
+30% +$194K 0.03% 470
2025
Q2 		$603K Buy
4,314
+231
+6% +$32.4K 0.02% 566
2025
Q1 		$600K Buy
4,083
+1,083
+36% +$157K 0.02% 547
2024
Q4 		$393K Sell
3,000
-748
-20% -$105K 0.01% 693
2024
Q3 		$584K Sell
3,748
-7,783
-67% -$1.26M 0.02% 547
2024
Q2 		$1.8M Buy
11,531
+278
+2% +$41.8K 0.06% 215
2024
Q1 		$1.52M Buy
11,253
+7,250
+181% +$960K 0.06% 264
2023
Q4 		$539K Sell
4,003
-226
-5% -$29.4K 0.02% 528
2023
Q3 		$573K Sell
4,229
-94
-2% -$12.8K 0.03% 474
2023
Q2 		$619K Sell
4,323
-1,447
-25% -$213K 0.03% 472
2023
Q1 		$801K Sell
5,770
-949
-14% -$128K 0.04% 389
2022
Q4 		$911K Sell
6,719
-856
-11% -$107K 0.05% 324
2022
Q3 		$831K Sell
7,575
-321
-4% -$40.7K 0.05% 334
2022
Q2 		$1.04M Buy
7,896
+382
+5% +$50.1K 0.06% 280
2022
Q1 		$997K Buy
7,514
+418
+6% +$50.1K 0.05% 346
2021
Q4 		$827K Sell
7,096
-730
-9% -$85.9K 0.04% 433
2021
Q3 		$940K Buy
7,826
+1,641
+27% +$191K 0.04% 372
2021
Q2 		$741K Sell
6,185
-715
-10% -$78.4K 0.04% 465
2021
Q1 		$686K Buy
6,900
+539
+8% +$54.2K 0.04% 451
2020
Q4 		$636K Buy
6,361
+41
+0.6% +$4.34K 0.06% 381
2020
Q3 		$693K Buy
6,320
+663
+12% +$73.7K 0.07% 315
2020
Q2 		$598K Buy
5,657
+370
+7% +$38.2K 0.06% 361
2020
Q1 		$472K Buy
5,287
+722
+16% +$68K 0.06% 371
2019
Q4 		$455K Sell
4,565
-208
-4% -$19.6K 0.04% 510
2019
Q3 		$425K Sell
4,773
-225
-5% -$19.5K 0.04% 505
2019
Q2 		$413K Sell
4,998
-157
-3% -$12.3K 0.04% 509
2019
Q1 		$417K Buy
5,155
+55
+1% +$4.33K 0.04% 470
2018
Q4 		$387K Buy
5,100
+1,150
+29% +$89.8K 0.05% 445
2018
Q3 		$313K Sell
3,950
-183
-4% -$13.8K 0.04% 566
2018
Q2 		$290K Sell
4,133
-46
-1% -$3.31K 0.04% 571
2018
Q1 		$292K Sell
4,179
-134
-3% -$9.28K 0.04% 534
2017
Q4 		$299K Sell
4,313
-1,439
-25% -$97K 0.04% 548
2017
Q3 		$390K Sell
5,752
-132
-2% -$8.34K 0.05% 471
2017
Q2 		$401K Sell
5,884
-715
-11% -$46.7K 0.05% 452
2017
Q1 		$411K Buy
6,599
+364
+6% +$21.2K 0.06% 412
2016
Q4 		$341K Buy
6,235
+2,958
+90% +$168K 0.05% 451
2016
Q3 		$215K Buy
+3,277
New +$214K 0.03% 648
2014
Q4 		– Sell
-4,070
Closed -$291K – 715
2014
Q3 		$291K Sell
4,070
-2,244
-36% -$164K 0.05% 410
2014
Q2 		$469K Buy
6,314
+2,389
+61% +$173K 0.07% 271
2014
Q1 		$255K Sell
3,925
-3,556
-48% -$230K 0.04% 418
2013
Q4 		$444K Buy
+7,481
New +$406K 0.1% 230
2013
Q3 		– Sell
-4,527
Closed -$214K – 583
2013
Q2 		$214K Buy
+4,527
New +$231K 0.06% 396

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Wedbush Securities's AZN Position: Q1 2026 in Review

Wedbush Securities reduced its AstraZeneca (AZN) stake by 1.2% in Q1 2026, selling an estimated $16.6K and leaving 6,964 shares worth $1.37M. The position accounts for 0.04% of the portfolio, ranked #360.

Wedbush Securities first reported a position in AZN in Q2 2013 and has held it in 44 quarters since. The position peaked at $1.8M in Q2 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Wedbush Securities held 6,964 shares of AstraZeneca worth $1.37M as of Q1 2026.
  • Wedbush Securities sold 86 AstraZeneca shares in Q1 2026, an estimated $16.6K.
  • AstraZeneca made up 0.04% of Wedbush Securities's portfolio in Q1 2026, its #360 holding.
  • Wedbush Securities first reported a position in AstraZeneca in Q2 2013 and has held it in 44 quarters since.
  • Wedbush Securities's AstraZeneca position peaked at $1.8M in Q2 2024.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.